Switch theme
Sign up to access all valuation multiples
Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.
2001
10.5K+
LTM Revenue $1.4B
LTM EBITDA $378M
$4.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hypera has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $378M.
In the most recent fiscal year, Hypera achieved revenue of $1.3B and an EBITDA of $392M.
Hypera expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hypera valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $806M | XXX | $770M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $378M | XXX | $392M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $326M | XXX | $316M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $217M | XXX | $236M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hypera's stock price is BRL 25 (or $4).
Hypera has current market cap of BRL 16.1B (or $2.8B), and EV of BRL 23.6B (or $4.2B).
See Hypera trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.2B | $2.8B | XXX | XXX | XXX | XXX | $0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hypera has market cap of $2.8B and EV of $4.2B.
Hypera's trades at 3.2x EV/Revenue multiple, and 10.6x EV/EBITDA.
Equity research analysts estimate Hypera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hypera has a P/E ratio of 13.0x.
See valuation multiples for Hypera and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBIT | 12.7x | XXX | 13.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.0x | XXX | 12.0x | XXX | XXX | XXX |
| EV/FCF | 27.1x | XXX | 13.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHypera's last 12 month revenue growth is 15%
Hypera's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $43K for the same period.
Hypera's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hypera's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hypera and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | -12% | XXX | XXX | XXX |
| Rule of 40 | 52% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $43K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hypera acquired XXX companies to date.
Last acquisition by Hypera was XXXXXXXX, XXXXX XXXXX XXXXXX . Hypera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hypera founded? | Hypera was founded in 2001. |
| Where is Hypera headquartered? | Hypera is headquartered in Brazil. |
| How many employees does Hypera have? | As of today, Hypera has 10.5K+ employees. |
| Is Hypera publicy listed? | Yes, Hypera is a public company listed on BVMF. |
| What is the stock symbol of Hypera? | Hypera trades under HYPE3 ticker. |
| When did Hypera go public? | Hypera went public in 2008. |
| Who are competitors of Hypera? | Similar companies to Hypera include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hypera? | Hypera's current market cap is $2.8B |
| What is the current revenue of Hypera? | Hypera's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Hypera? | Hypera revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Hypera? | Current revenue multiple of Hypera is 3.0x. |
| Is Hypera profitable? | Yes, Hypera is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hypera? | Hypera's last 12 months EBITDA is $378M. |
| What is Hypera's EBITDA margin? | Hypera's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Hypera? | Current EBITDA multiple of Hypera is 11.0x. |
| What is the current FCF of Hypera? | Hypera's last 12 months FCF is $153M. |
| What is Hypera's FCF margin? | Hypera's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Hypera? | Current FCF multiple of Hypera is 27.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
